Sudden death from genetic and acquired cardiomyopathies

Circulation

Volumn 125, Issue 12, 2012, Pages 1563-1576

  Sen Chowdhry, Srijita ^a,b   McKenna, William J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

arrhythmogenic right ventricular cardiomyopathy; cardiomyopathy; dilated cardiomyopathy; hypertrophic cardiomyopathy; sudden death

Indexed keywords

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MUSCULAR DYSTROPHY; PRIORITY JOURNAL; SUDDEN DEATH; SURVIVAL RATE;

ANIMALS; CARDIOMYOPATHIES; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN, CARDIAC; HUMANS;

EID: 84859082866     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.025528     Document Type: Article

References (103)

1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies. a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-276.
2. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, Tome Esteban MT, McKenna WJ. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;92:785-791.
3. Pinamonti B, Dragos AM, Pyxaras SA, Merlo M, Pivetta A, Barbati G, Di Lenarda A, Morgera T, Mestroni L, Sinagra G. Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy. Results from a 10-year registry. Eur Heart J. 2011;32:1105-1113.
4. Michels VV, Driscoll DJ, Miller FA, Olson TM, Atkinson EJ, Olswold CL, Schaid DJ. Progression of familial and non-familial dilated cardiomyopathy. long term follow up. Heart. 2003;89:757-761.
5. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981; 47:532-538.
6. Koga Y, Ogata M, Kihara K, Tsubaki K, Toshima H. Sudden death in hypertrophic and dilated cardiomyopathy. Jpn Circ J. 1989;53: 1546-1556.
7. Merner ND, Hodgkinson KA, Haywood AFM, Connors S, French VM, Drenckhahn J, Kupprion C, Ramadanova K, Thierfelder L, McKenna W, Gallagher B, Morris-Larkin L, Bassett AS, Parfrey PS, Young T. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet. 2008;82:809-821.
8. Blomström-Lundqvist C, Sabel KG, Olsson SB. A long term follow up of 15 patients with arrhythmogenic right ventricular dysplasia. Br Heart J. 1987;58:477-488.
9. Berder V, Vauthier M, Mabo P, De Place C, Laurent M, Almange C, Daubert C. Characteristics and outcome in arrhythmogenic right ventricular dysplasia. Am J Cardiol. 1995;75:411-414.
10. Marcus FI, Fontaine GH, Frank R, Gallagher JJ, Reiter MJ. Long-term follow-up in patients with arrhythmogenic right ventricular disease. Eur Heart J. 1989;10(suppl D):68-73.
11. Leclercq JF, Coumel P. Characteristics, prognosis and treatment of the ventricular arrhythmias of right ventricular dysplasia. Eur Heart J. 1989;10(suppl D):61-67.
12. Lemery R, Brugada P, Janssen J, Cheriex E, Dugernier T, Wellens HJ. Nonischemic sustained ventricular tachycardia. clinical outcome in 12 patients with arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol. 1989;14:96-105.
13. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NAM; Buja G, Thiene G. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003;108: 3084-3091.
14. Wichter T, Paul M, Wollmann C, Acil T, Gerdes P, Ashraf O, Tjan TDT, Soeparwata R, Block M, Borggrefe M, Scheld HH, Breithardt G, Böcker D. Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy. Single-center experience of long-term follow-up and complications in 60 patients. Circulation. 2004;109: 1503-1508.
15. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, Shalaby A, Schaechter A, Subacius H, Kadish A. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation. 2006;113:776-782.
16. Nava A, Bauce B, Basso C, Muriago M, Rampazzo A, Villanova C, Daliento L, Buja G, Corrado D, Danieli GA, Thiene G. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2000;36:2226-2233.
17. Bauce B, Basso C, Rampazzo A, Beffagna G, Daliento L, Frigo G, Malacrida S, Settimo L, Danieli G, Thiene G, Nava A. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J. 2005;26: 1666-1675.
18. Sen-Chowdhry S, Morgan RD, Chambers JC, McKenna WJ. Arrhythmogenic cardiomyopathy. etiology, diagnosis, and treatment. Annu Rev Med. 2010;61:233-253.
19. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, Pennell DJ, McKenna WJ. Left-dominant arrhythmogenic cardiomyopathy. an under-recognized clinical entity. J Am Coll Cardiol. 2008; 52:2175-2187.
20. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007;115: 1710-1720.
21. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol. 1990;65:42I-48I.
22. Hermans MCE, Pinto YM, Merkies ISJ, de Die-Smulders CEM, Crijns HJGM, Faber CG. Hereditary muscular dystrophies and the heart. Neuromuscul Disord. 2010;20:479-492.
23. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990; 26:271-277.
24. Nigro G, Comi LI, Politano L, Limongelli FM, Nigro V, De Rimini ML, Giugliano MA, Petretta VR, Passamano L, Restucci B, Fattore L, Tebloev K, Comi L, De Luca F, Raia P, Esposito MG. Evaluation of the cardiomyopathy in Becker muscular dystrophy. Muscle Nerve. 1995;18: 283-291.
25. Duboc D, Meune C, Lerebours G, Devaux J, Vaksmann G, Bécane H. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005; 45:855-857.
26. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141-157.
27. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, Machac J, Teirstein A. Cardiac involvement in patients with sarcoidosis. diagnostic and prognostic value of outpatient testing. Chest. 2008;133:1426-1435.
28. Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, Homma AH, Mikami R, Hongo O, Hiraga Y, Yamamoto M. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278:455-469.
29. Roberts WC, McAllister HAJ, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977; 63:86-108.
30. Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis. role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4:43-48.
31. Sen-Chowdhry S, McKenna WJ. Sudden cardiac death in the young. a strategy for prevention by targeted evaluation. Cardiology. 2006;105: 196-206.
32. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes. analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119:1085-1092.
33. de Noronha SV, Sharma S, Papadakis M, Desai S, Whyte G, Sheppard MN. Aetiology of sudden cardiac death in athletes in the United Kingdom. a pathological study. Heart. 2009;95:1409-1414.
34. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults?. J Am Coll Cardiol. 2003;42:1959-1963.
35. Tabib A, Loire R, Chalabreysse L, Meyronnet D, Miras A, Malicier D, Thivolet F, Chevalier P, Bouvagnet P. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation. 2003;108:3000-3005.
36. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy. a profile of 78 patients. Circulation. 1982;65: 1388-1394.
37. Maron BJ, Kogan J, Proschan MA, Hecht GM, Roberts WC. Circadian variability in the occurrence of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1994;23:1405-1409.
38. Dalal D, Nasir K, Bomma C, Prakasa K, Tandri H, Piccini J, Roguin A, Tichnell C, James C, Russell SD, Judge DP, Abraham T, Spevak PJ, Bluemke DA, Calkins H. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005;112:3823-3832.
39. Maron BJ, Spirito P, Shen W, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA III; Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverterdefibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405-412.
40. Sen-Chowdhry S, McKenna WJ. Non-invasive risk stratification in hypertrophic cardiomyopathy: don't throw out the baby with the bathwater. Eur Heart J. 2008;29:1600-1602.
41. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001;88:275-279.
42. Sen-Chowdhry S, McKenna WJ. Reconciling the protean manifestations of arrhythmogenic cardiomyopathy. Circ Arrhythm Electrophysiol. 2010;3:566-570.
43. Ellison KE, Friedman PL, Ganz LI, Stevenson WG. Entrainment mapping and radiofrequency catheter ablation of ventricular tachycardia in right ventricular dysplasia. J Am Coll Cardiol. 1998;32:724-728.
44. Kaplan SR, Gard JJ, Protonotarios N, Tsatsopoulou A, Spiliopoulou C, Anastasakis A, Squarcioni CP, McKenna WJ, Thiene G, Basso C, Brousse N, Fontaine G, Saffitz JE. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm. 2004;1:3-11.
45. Pilichou K, Remme CA, Basso C, Campian ME, Rizzo S, Barnett P, Scicluna BP, Bauce B, van den Hoff MJB, de Bakker JMT, Tan HL, Valente M, Nava A, Wilde AAM, Moorman AFM, Thiene G, Bezzina CR. Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy. J Exp Med. 2009;206:1787-1802.
46. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007;50:1813-1821.
47. Kirchhof P, Fabritz L, Zwiener M, Witt H, Schäfers M, Zellerhoff S, Paul M, Athai T, Hiller K, Baba HA, Breithardt G, Ruiz P, Wichter T, Levkau B. Age-and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation. 2006;114:1799-1806.
48. Wu TJ, Ong JJ, Hwang C, Lee JJ, Fishbein MC, Czer L, Trento A, Blanche C, Kass RM, Mandel WJ, Karagueuzian HS, Chen PS. Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy. role of increased fibrosis in the generation of reentry. J Am Coll Cardiol. 1998;32:187-196.
49. Hsia HH, Marchlinski FE. Electrophysiology studies in patients with dilated cardiomyopathies. Card Electrophysiol Rev. 2002;6:472-481.
50. Pogwizd SM, McKenzie JP, Cain ME. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation. 1998;98:2404-2414.
51. Waters DD, Nutter DO, Hopkins LC, Dorney ER. Cardiac features of an unusual X-linked humeroperoneal neuromuscular disease. N Engl J Med. 1975;293:1017-1022.
52. Buckley AE, Dean J, Mahy IR. Cardiac involvement in Emery Dreifuss muscular dystrophy. a case series. Heart. 1999;82:105-108.
53. Ishikawa K, Mimuro M, Tanaka T. Ventricular arrhythmia in X-linked Emery-Dreifuss muscular dystrophy. a lesson from an autopsy case. Intern Med. 2011;50:459-462.
54. Gueneau L, Bertrand AT, Jais J, Salih MA, Stojkovic T, Wehnert M, Hoeltzenbein M, Spuler S, Saitoh S, Verschueren A, Tranchant C, Beuvin M, Lacene E, Romero NB, Heath S, Zelenika D, Voit T, Eymard B, Ben Yaou R, Bonne G. Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Am J Hum Genet. 2009;85:338-353.
55. Hong J, Ki C, Kim J, Suh Y, Kim JS, Baek KK, Kim BJ, Ahn KJ, Kim D. Cardiac dysrhythmias, cardiomyopathy and muscular dystrophy in patients with Emery-Dreifuss muscular dystrophy and limb-girdle muscular dystrophy type 1B. J Korean Med Sci. 2005;20:283-290.
56. Malhotra R, Mason PK. Lamin A/C deficiency as a cause of familial dilated cardiomyopathy. Curr Opin Cardiol. 2009;24:203-208.
57. Bushby K, Muntoni F, Bourke JP. 107Th ENMC international Workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, The Netherlands. Neuromuscul Disord. 2003;13:166-172.
58. Sun L, Wang L, Wang H, Zhang Y, Pu J. Connexin 43 remodeling induced by LMNA gene mutation Glu82Lys in familial dilated cardiomyopathy with atrial ventricular block. Chin Med J (Engl). 2010;123: 1058-1062.
59. Nugent AW, Daubeney PEF, Chondros P, Carlin JB, Colan SD, Cheung M, Davis AM, Chow CW, Weintraub RG. Clinical features and outcomes of childhood hypertrophic cardiomyopathy. results from a national population-based study. Circulation. 2005;112:1332-1338.
60. Sovari AA, Bodine CK, Farokhi F. Cardiovascular manifestations of myotonic dystrophy-1. Cardiol Rev. 2007;15:191-194.
61. Lazarus A, Varin J, Ounnoughene Z, Radvanyi H, Junien C, Coste J, Laforet P, Eymard B, Becane HM, Weber S, Duboc D. Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy. Circulation. 1999; 99:1041-1046.
62. Hermans MCE, Faber CG, Pinto YM. Sudden death in myotonic dystrophy. N Engl J Med. 359:1626-1628, 2008; author reply 1328-1329.
63. Merino JL, Peinado R, Sobrino JA. Sudden death in myotonic dystrophy. the potential role of bundle-branch reentry. Circulation. 2000; 101:E73.
64. Nguyen HH, Wolfe JTE, Holmes DRJ, Edwards WD. Pathology of the cardiac conduction system in myotonic dystrophy. a study of 12 cases. J Am Coll Cardiol. 1988;11:662-671.
65. Merino JL, Carmona JR, Fernández-Lozano I, Peinado R, Basterra N, Sobrino JA. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy. implications for catheter ablation. Circulation. 1998;98:541-546.
66. Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, Ogo KO, Nishii N, Watanabe A, Nagase S, Sakuragi S, Ohe T. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm. 2007;4:1292-1299.
67. Furushima H, Chinushi M, Sugiura H, Kasai H, Washizuka T, Aizawa Y. Ventricular tachyarrhythmia associated with cardiac sarcoidosis. its mechanisms and outcome. Clin Cardiol. 2004;27:217-222.
68. Hess EP, White RD. Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: presenting rhythms, management and outcomes in four patients. Resuscitation. 2004;60:105-111.
69. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack F, Voss F, Becker R, Katus HA, Bauer A. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5: 235-240.
70. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36: 2212-2218.
71. Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA, Selvanayagam JB, Neubauer S, Watkins H. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy. new insights from multiparametric magnetic resonance imaging. Circulation. 2007;115:2418-2425.
72. Maron BJ, Haas TS, Shannon KM, Almquist AK, Hodges JS. Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. Heart Rhythm. 2009;6:993-997.
73. McKenna W, Elliott P. Hypertrophic cardiomyopathy. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:492.
74. Thaman R, Elliott PM, Shah JS, Mist B, Williams L, Murphy RT, McKenna WJ, Frenneaux MP. Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:883-892.
75. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J. 1985;53:412-416.
76. Nishimura RA, Ommen SR. Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators. how low the bar? JAMA. 2007;298:452-454.
77. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044-2051.
78. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008;5:158-168.
79. Saumarez RC, Pytkowski M, Sterlinski M, Bourke JP, Clague JR, Cobbe SM, Connelly DT, Griffith MJ, McKeown PP, McLeod K, Morgan JM, Sadoul N, Chojnowska L, Huang CL, Grace AA. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J. 2008;29:1653-1661.
80. Moon JCC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561-1567.
81. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867-874.
82. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert E, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875-887.
83. Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992;86:29-37.
84. Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, Estes NA III, Marcus F, Scheinman MM. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol. 2009;54: 609-615.
85. Wichter T, Paul TM, Eckardt L, Gerdes P, Kirchhof P, Böcker D, Breithardt G. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz. 2005;30:91-101.
86. Roguin A, Bomma CS, Nasir K, Tandri H, Tichnell C, James C, Rutberg J, Crosson J, Spevak PJ, Berger RD, Halperin HR, Calkins H. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2004; 43:1843-1852.
87. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes NAM, Wichter T, McKenna WJ, Thiene G, Marcus FI. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation. 2010;122:1144-1152.
88. Baumwart RD, Orvalho J, Meurs KM. Evaluation of serum cardiac troponin I concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res. 2007;68:524-528.
89. Kostis WJ, Tedford RJ, Miller DL, Schulman SP, Tomaselli GF. Troponin-I elevation in a young man with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Interv Card Electrophysiol. 2008;22: 49-53.
90. Bauce B, Nava A, Beffagna G, Basso C, Lorenzon A, Smaniotto G, De Bortoli M, Rigato I, Mazzotti E, Steriotis A, Marra MP, Towbin JA, Thiene G, Danieli GA, Rampazzo A. Multiple mutations in desmosomal proteins encoding genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm. 2010;7:22-29.
91. Xu T, Yang Z, Vatta M, Rampazzo A, Beffagna G, Pilichou K, Scherer SE, Saffitz J, Kravitz J, Zareba W, Danieli GA, Lorenzon A, Nava A, Bauce B, Thiene G, Basso C, Calkins H, Gear K, Marcus F, Towbin JA. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2010;55:587-597.
92. Wijetunga M, Strickberger SA. Amiodarone versus Implantable Defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications. Card Electrophysiol Rev. 2003;7:452-456.
93. Grimm W, Alter P, Maisch B. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT. Herz. 2004;29:348-352.
94. Shekha K, Ghosh J, Thekkoott D, Greenberg Y. Risk stratification for sudden cardiac death in patients with non-ischemic dilated cardiomyopathy. Indian Pacing Electrophysiol J. 2005;5:122-138.
95. McLeod CJ, Shen W, Rea RF, Friedman PA, Hayes DL, Wokhlu A, Webster TL, Wiste HJ, Hodge DO, Bradley DJ, Hammill SC, Packer DL, Cha Y. Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy. Heart Rhythm. 2011;8:377-382.
96. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NAM; Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-1338.
97. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, Greenberg H, Hall WJ, McNitt S, Zareba W, Solomon S, Steinberg JS. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol. 2011;57:813-820.
98. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977-1985.
99. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, Mannarino S, Gambarin F, Favalli V, Grasso M, Agozzino M, Campana C, Gavazzi A, Febo O, Marini M, Landolina M, Mortara A, Piccolo G, Viganò M, Tavazzi L, Arbustini E. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52: 1250-1260.
100. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, Izumi T, Sekiguchi M. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006-1010.
101. Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16: 140-147.
102. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009; 120:1969-1977.
103. Lubitz SA, Goldbarg SH, Mehta D. Sudden cardiac death in infiltrative cardiomyopathies. sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog Cardiovasc Dis. 2008;51:58-73.